Flexion Therapeutics Announces Publication of Results from Pivotal Phase 3 Study of ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) in the Journal of Bone and Joint Surgery

Ads

You May Also Like

VBL Therapeutics Announces Closing of $15.5 Million Registered Direct Offering

TEL AVIV, Israel, June 27, 2018 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology ...

Zogenix to Participate in Two Upcoming Investor Conferences

EMERYVILLE, Calif., Sept. 20, 2016 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company ...

United Health Products Issues Update on HemoStyp®South Korea MFDS Application

HENDERSON, Nev., Jan. 30, 2018 (GLOBE NEWSWIRE) -- United Health Products, Inc. (UHP) (OTC:UEEC), ...